N-hydroxy-N'-phenyloctanediamide
| Title | Journal |
|---|---|
| Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. | The Journal of biological chemistry 20180216 |
| Valproic acid disrupts the oscillatory expression of core circadian rhythm transcription factors. | Toxicology and applied pharmacology 20180115 |
| The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition. | Antimicrobial agents and chemotherapy 20170801 |
| Butyrate alters expression of cytochrome P450 1A1 and metabolism of benzo[a]pyrene via its histone deacetylase activity in colon epithelial cell models. | Archives of toxicology 20170501 |
| Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Tox(ukn) and STOP-Tox(ukk) tests. | Archives of toxicology 20170101 |
| Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. | Oncotarget 20160906 |
| Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms. | Toxicological sciences : an official journal of the Society of Toxicology 20160901 |
| Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line. | The Journal of international medical research 20160801 |
| Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation. | Transplantation 20160801 |
| An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells. | Chemico-biological interactions 20160625 |
| Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. | Cancer research 20160415 |
| Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. | The Journal of clinical endocrinology and metabolism 20160301 |
| The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. | Biochemical pharmacology 20160215 |
| Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. | Nature medicine 20151001 |
| Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. | Neurotoxicology 20150901 |
| Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. | Oncotarget 20150814 |
| Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | Toxicological sciences : an official journal of the Society of Toxicology 20150601 |
| In vitro and in vivo evaluation of novel cinnamyl sulfonamide hydroxamate derivative against colon adenocarcinoma. | Chemico-biological interactions 20150525 |
| Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. | Chemistry & biology 20150219 |
| Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine. | Journal of pharmaceutical sciences 20150101 |
| A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. | Archives of toxicology 20150101 |
| HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. | Cell death & disease 20141001 |
| Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. | Cancer letters 20140828 |
| Prenatal alcohol exposure causes the over-expression of DHAND and EHAND by increasing histone H3K14 acetylation in C57 BL/6 mice. | Toxicology letters 20140804 |
| Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. | Nature neuroscience 20140701 |
| Class I to III histone deacetylases differentially regulate inflammation-induced matrix metalloproteinase 9 expression in primary amnion cells. | Reproductive sciences (Thousand Oaks, Calif.) 20140601 |
| Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. | Oncotarget 20140501 |
| Yin Yang 1 is a repressor of glutamate transporter EAAT2, and it mediates manganese-induced decrease of EAAT2 expression in astrocytes. | Molecular and cellular biology 20140401 |
| Synthesis, antimalarial properties, and SAR studies of alkoxyurea-based HDAC inhibitors. | ChemMedChem 20140301 |
| Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. | PloS one 20140101 |
| Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. | Journal of natural products 20131122 |
| Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation. | Toxicology 20131004 |
| Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. | ACS medicinal chemistry letters 20130808 |
| Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. | Molecular cancer therapeutics 20130801 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Basic nuclear processes affected by histone acetyltransferases and histone deacetylase inhibitors. | Epigenomics 20130801 |
| A genomic approach to predict synergistic combinations for breast cancer treatment. | The pharmacogenomics journal 20130201 |
| Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells. | Frontiers in oncology 20130101 |
| SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. | PloS one 20130101 |
| Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. | Investigational new drugs 20121201 |
| Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. | Molecular pharmacology 20121201 |
| The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. | Bioorganic & medicinal chemistry letters 20121201 |
| Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. | The Journal of biological chemistry 20121102 |
| Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase. | European journal of cancer (Oxford, England : 1990) 20121101 |
| Histone deacetylase inhibitors preserve function in aging axons. | Journal of neurochemistry 20121101 |
| Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121101 |
| Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. | International journal of cancer 20121015 |
| Induced production of mycotoxins in an endophytic fungus from the medicinal plant Datura stramonium L. | Bioorganic & medicinal chemistry letters 20121015 |
| Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. | The Journal of dermatology 20121001 |
| Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. | Journal of pharmaceutical sciences 20121001 |
| Curbing autophagy and histone deacetylases to kill cancer cells. | Autophagy 20121001 |
| Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. | Bioorganic & medicinal chemistry letters 20121001 |
| Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. | Epigenetics 20121001 |
| Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. | Clinical lymphoma, myeloma & leukemia 20121001 |
| Use of reprogrammed cells to identify therapy for respiratory papillomatosis. | The New England journal of medicine 20120927 |
| Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin. | International journal of cancer 20120915 |
| Efficacy and safety of suberoylanilide hydroxamic acid (Vorinostat) in the treatment of canine corneal fibrosis. | Veterinary ophthalmology 20120901 |
| Early prediction of response to Vorinostat in an orthotopic rat glioma model. | NMR in biomedicine 20120901 |
| Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat. | American journal of hematology 20120901 |
| Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability. | Toxicology and applied pharmacology 20120901 |
| Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. | Breast cancer research and treatment 20120901 |
| HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. | Nature neuroscience 20120901 |
| Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. | Cell cycle (Georgetown, Tex.) 20120901 |
| Emerging biological insights and novel treatment strategies in multiple myeloma. | Expert opinion on emerging drugs 20120901 |
| SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. | Cellular & molecular immunology 20120901 |
| Creating a 'pro-survival' phenotype through epigenetic modulation. | Surgery 20120901 |
| The [(Cp)M(CO)(3)] (M=Re, (99m)Tc) building block for imaging agents and bioinorganic probes: perspectives and limitations. | Chemistry & biodiversity 20120901 |
| [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells]. | Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20120901 |
| Cancer research: Open ambition. | Nature 20120809 |
| A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. | Investigational new drugs 20120801 |
| Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. | Leukemia & lymphoma 20120801 |
| Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. | Cell death and differentiation 20120801 |
| HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. | Leukemia research 20120801 |
| Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120801 |
| Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120801 |
| LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120801 |
| Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. | Molecular cancer research : MCR 20120801 |
| Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2. | Bioorganic & medicinal chemistry letters 20120801 |
| HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. | Anticancer research 20120801 |
| REST is a novel prognostic factor and therapeutic target for medulloblastoma. | Molecular cancer therapeutics 20120801 |
| [Novel therapeutic approach for the treatment of post-traumatic stress disorder (PTSD): facilitating fear extinction]. | Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20120801 |
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. | Nature 20120726 |
| Scientists investigate routing latent HIV from its reservoirs to achieve a cure. | JAMA 20120725 |
| HIV: Shock and kill. | Nature 20120725 |
| Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. | Circulation 20120724 |
| Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy. | International journal of radiation oncology, biology, physics 20120715 |
| Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors. | Bioorganic & medicinal chemistry 20120715 |
| Histone deacetylase inhibitors induce mitochondrial elongation. | Journal of cellular physiology 20120701 |
| SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. | Pathology oncology research : POR 20120701 |
| Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells. | Oncology reports 20120701 |
| Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. | Antimicrobial agents and chemotherapy 20120701 |
| Selenium-containing histone deacetylase inhibitors for melanoma management. | Cancer biology & therapy 20120701 |
| The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. | Seminars in hematology 20120701 |
| Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. | Anticancer research 20120701 |
| Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120620 |
| Growth stimulating effect on queen bee larvae of histone deacetylase inhibitors. | Journal of agricultural and food chemistry 20120620 |
| Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. | Oncogene 20120614 |
| Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme. | Journal of medicinal chemistry 20120614 |
| Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. | Hepatology (Baltimore, Md.) 20120601 |
| Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. | Leukemia 20120601 |
| Repression of PDGF-R-α after cellular injury involves TNF-α, formation of a c-Fos-YY1 complex, and negative regulation by HDAC. | American journal of physiology. Cell physiology 20120601 |
| Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. | Neurotoxicology 20120601 |
| Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells. | Leukemia research 20120601 |
| Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. | Biomaterials 20120601 |
| Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. | Cancer biology & therapy 20120601 |
| Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. | Leukemia research 20120601 |
| A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells. | Cancer biology & therapy 20120601 |
| Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. | Journal of pediatric surgery 20120601 |
| Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. | Blood 20120531 |
| Novel molecular targeted therapies for refractory thyroid cancer. | Head & neck 20120501 |
| Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. | Leukemia & lymphoma 20120501 |
| Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. | Haematologica 20120501 |
| Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. | European journal of cancer (Oxford, England : 1990) 20120501 |
| Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest. | Biochemical pharmacology 20120501 |
| An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. | Current cancer drug targets 20120501 |
| Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells. | International journal of oncology 20120501 |
| Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. | Journal of psychiatric research 20120501 |
| Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. | Cancer biology & therapy 20120501 |
| Suberoylanilide hydroxamic acid enhances odontoblast differentiation. | Journal of dental research 20120501 |
| Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. | Journal of immunology (Baltimore, Md. : 1950) 20120501 |
| Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120501 |
| Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. | Journal of medicinal chemistry 20120426 |
| Efficacy of vorinostat in a murine model of polycythemia vera. | Blood 20120419 |
| MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. | Cell cycle (Georgetown, Tex.) 20120415 |
| Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead. | Journal of medicinal chemistry 20120412 |
| Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells. | Biochemical and biophysical research communications 20120406 |
| Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. | Investigational new drugs 20120401 |
| Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. | BJU international 20120401 |
| Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. | Breast cancer research and treatment 20120401 |
| Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes. | International immunopharmacology 20120401 |
| Vorinostat: a potent agent to prevent and treat laser-induced corneal haze. | Journal of refractive surgery (Thorofare, N.J. : 1995) 20120401 |
| CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1. | Epigenetics 20120401 |
| Novel therapeutics in multiple myeloma. | Hematology (Amsterdam, Netherlands) 20120401 |
| A case of Sweet's syndrome due to 5-Azacytidine and vorinostat in a patient with NK/T cell lymphoma. | Cutaneous and ocular toxicology 20120301 |
| A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. | Cancer chemotherapy and pharmacology 20120301 |
| New generation small-molecule inhibitors in myeloproliferative neoplasms. | Current opinion in hematology 20120301 |
| HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. | Future medicinal chemistry 20120301 |
| Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. | Cancer letters 20120227 |
| Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. | Journal of medicinal chemistry 20120223 |
| Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. | Journal of medicinal chemistry 20120223 |
| Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120215 |
| Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation. | The Journal of biological chemistry 20120210 |
| Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. | Oncogene 20120202 |
| Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms. | Journal of proteomics 20120202 |
| Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. | Investigational new drugs 20120201 |
| Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. | Investigational new drugs 20120201 |
| A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. | Leukemia & lymphoma 20120201 |
| SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. | Biochimie 20120201 |
| Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors. | International journal of molecular medicine 20120201 |
| Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. | Neuro-oncology 20120201 |
| Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. | Journal of leukocyte biology 20120201 |
| Role for Class I histone deacetylases in multidrug resistance. | Experimental cell research 20120201 |
| Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20120201 |
| Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study. | The journal of trauma and acute care surgery 20120201 |
| Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120115 |
| Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases. | Bioorganic & medicinal chemistry 20120115 |
| Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. | British journal of cancer 20120103 |
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. | British journal of pharmacology 20120101 |
| Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. | Advances in hematology 20120101 |
| The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas. | Advances in hematology 20120101 |
| miRNAs and Melanoma: How Are They Connected? | Dermatology research and practice 20120101 |
| Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. | Neuro-oncology 20120101 |
| NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| HDAC inhibitors in HIV. | Immunology and cell biology 20120101 |
| HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. | Immunology and cell biology 20120101 |
| Novel therapies in phase II and III trials for malignant pleural mesothelioma. | Journal of the National Comprehensive Cancer Network : JNCCN 20120101 |
| Emerging therapies in hematopoietic stem cell transplantation. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120101 |
| A searchable cross-platform gene expression database reveals connections between drug treatments and disease. | BMC genomics 20120101 |
| Linear Discriminant Functions in Connection with the micro-RNA Diagnosis of Colon Cancer. | Cancer informatics 20120101 |
| Modularity in protein complex and drug interactions reveals new polypharmacological properties. | PloS one 20120101 |
| Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. | PloS one 20120101 |
| A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. | Oncotarget 20120101 |
| ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. | PloS one 20120101 |
| Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. | PloS one 20120101 |
| Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. | Clinical Medicine Insights. Oncology 20120101 |
| Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. | Scientific reports 20120101 |
| Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells. | PloS one 20120101 |
| Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors. | PloS one 20120101 |
| Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells. | PloS one 20120101 |
| AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy. | Advances in hematology 20120101 |
| Clinical efficacy of vorinostat in a patient with leiomyosarcoma. | Clinical Medicine Insights. Oncology 20120101 |
| Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies. | AIDS research and therapy 20120101 |
| Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. | Clinical epigenetics 20120101 |
| Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. | Cancer management and research 20120101 |
| In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. | Radiation oncology (London, England) 20120101 |
| Triple-negative breast cancer: an update on neoadjuvant clinical trials. | International journal of breast cancer 20120101 |
| Regulation of immune responses by histone deacetylase inhibitors. | ISRN hematology 20120101 |
| Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. | PloS one 20120101 |
| Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. | Journal of oncology 20120101 |
| Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells. | Neoplasma 20120101 |
| Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. | BMC cancer 20120101 |
| Novel Insights into the Interplay between Apoptosis and Autophagy. | International journal of cell biology 20120101 |
| Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. | Journal of Cancer 20120101 |
| Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. | PloS one 20120101 |
| Novel therapies in glioblastoma. | Neurology research international 20120101 |
| Current trends in targeted therapies for glioblastoma multiforme. | Neurology research international 20120101 |
| Novel therapies for aggressive B-cell lymphoma. | Advances in hematology 20120101 |
| Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? | Clinical Medicine Insights. Oncology 20120101 |
| Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. | Stem cells international 20120101 |
| Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer. | PloS one 20120101 |
| Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. | OncoTargets and therapy 20120101 |
| Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma. | ISRN oncology 20120101 |
| Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. | Clinical sarcoma research 20120101 |
| Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. | Clinical sarcoma research 20120101 |
| Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. | PloS one 20120101 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ. | Journal of neuroinflammation 20120101 |
| Epigenetics modifications and therapeutic prospects in human thyroid cancer. | Frontiers in endocrinology 20120101 |
| Acute myeloid leukemia: focus on novel therapeutic strategies. | Clinical Medicine Insights. Oncology 20120101 |
| Analyzing gene expression profile in K562 cells exposed to sodium valproate using microarray combined with the connectivity map database. | Journal of biomedicine & biotechnology 20120101 |
| Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. | Journal of biomedicine & biotechnology 20120101 |
| Targeted therapies in sarcomas: challenging the challenge. | Sarcoma 20120101 |
| Adult T-cell leukemia/lymphoma: a retroviral malady. | Indian journal of dermatology 20120101 |
| QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. | Cardiology journal 20120101 |
| The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma. | PloS one 20120101 |
| A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. | PloS one 20120101 |
| Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. | BMC urology 20120101 |
| Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. | PloS one 20120101 |
| Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. | Radiation oncology (London, England) 20120101 |
| [Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL]. | Biofizika 20120101 |
| Mechanisms of resistance to histone deacetylase inhibitors. | Advances in cancer research 20120101 |
| Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. | Bioorganic & medicinal chemistry letters 20111215 |
| Histone deacetylase inhibitors: emerging mechanisms of resistance. | Molecular pharmaceutics 20111205 |
| Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. | Journal of cellular physiology 20111201 |
| Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. | Journal of cellular and molecular medicine 20111201 |
| SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. | Cell death and differentiation 20111201 |
| Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas. | European journal of haematology 20111201 |
| Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma. | Oral oncology 20111201 |
| MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. | Endocrine-related cancer 20111201 |
| Identification of selective class II histone deacetylase inhibitors using a novel dual-parameter binding assay based on fluorescence anisotropy and lifetime. | Journal of biomolecular screening 20111201 |
| A new target for personalized medicine. | EMBO reports 20111201 |
| Diagnostic and prognostic markers in differentiated thyroid cancer. | Current genomics 20111201 |
| miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. | The Journal of biological chemistry 20111125 |
| Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. | Human molecular genetics 20111115 |
| Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. | Toxicology and applied pharmacology 20111115 |
| 4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors. | Bioorganic & medicinal chemistry letters 20111115 |
| Determination of HS270, a new histone deacetylase inhibitor, in rat plasma by LC-MS/MS--application to a preclinical pharmacokinetic study. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111115 |
| Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation. | Journal of medicinal chemistry 20111110 |
| Design, synthesis and biological evaluation of hydroxamic acid derivatives as potential high density lipoprotein (HDL) receptor CLA-1 up-regulating agents. | Molecules (Basel, Switzerland) 20111102 |
| Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. | Breast cancer research and treatment 20111101 |
| STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. | Inflammatory bowel diseases 20111101 |
| A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. | The European respiratory journal 20111101 |
| Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. | Journal of neuro-oncology 20111101 |
| Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. | Pharmacogenetics and genomics 20111101 |
| A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. | Acta neuropathologica 20111101 |
| HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes. | Journal of lipid research 20111101 |
| Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. | Molecular cancer therapeutics 20111101 |
| Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. | Current clinical pharmacology 20111101 |
| Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. | Journal of natural products 20111028 |
| p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. | The Journal of biological chemistry 20111028 |
| The use of molecular profiling for diagnosis and research in non-Hodgkin's lymphoma. | Hematology reports 20111028 |
| The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. | Bioorganic & medicinal chemistry letters 20111015 |
| Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. | Journal of controlled release : official journal of the Controlled Release Society 20111010 |
| Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. | Molecular pharmaceutics 20111003 |
| A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. | Investigational new drugs 20111001 |
| Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. | Cancer 20111001 |
| Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells. | Journal of cellular biochemistry 20111001 |
| Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. | American journal of physiology. Cell physiology 20111001 |
| Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds. | Current cancer drug targets 20111001 |
| MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays. | Biomaterials 20111001 |
| SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders. | Proteomics 20111001 |
| Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. | Epigenetics 20111001 |
| Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration. | Anticancer research 20111001 |
| Vitamin D deficiency in a man with multiple myeloma. | North American journal of medical sciences 20111001 |
| Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. | The Journal of biological chemistry 20110930 |
| Discovery, synthesis, and biological evaluation of novel SMN protein modulators. | Journal of medicinal chemistry 20110922 |
| Chemotherapy and targeted therapies for unresectable malignant mesothelioma. | Lung cancer (Amsterdam, Netherlands) 20110901 |
| Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. | Leukemia & lymphoma 20110901 |
| HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. | Journal of cellular physiology 20110901 |
| HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. | Apoptosis : an international journal on programmed cell death 20110901 |
| Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. | Cancer chemotherapy and pharmacology 20110901 |
| Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. | European journal of medicinal chemistry 20110901 |
| Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target. | Human reproduction (Oxford, England) 20110901 |
| Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. | Molecular cancer therapeutics 20110901 |
| Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. | Proteomics 20110901 |
| Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. | Leukemia & lymphoma 20110901 |
| Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide-induced shock. | Surgery 20110901 |
| Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. | Journal of medicinal chemistry 20110811 |
| In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). | Journal of medicinal chemistry 20110811 |
| Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. | Cancer chemotherapy and pharmacology 20110801 |
| Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells. | Molecular biology reports 20110801 |
| Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. | Pancreas 20110801 |
| Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines. | Oncology reports 20110801 |
| Structure-based optimization of click-based histone deacetylase inhibitors. | European journal of medicinal chemistry 20110801 |
| Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801 |
| Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. | Neuro-oncology 20110801 |
| Romidepsin: a novel histone deacetylase inhibitor for cancer. | Expert opinion on investigational drugs 20110801 |
| Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. | Bioorganic & medicinal chemistry 20110801 |
| [Histone deacetylase inhibitors in the treatment of hematological malignancies]. | Bulletin du cancer 20110801 |
| [Development of novel agents for multiple myeloma; now and the future]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801 |
| [Present status and perspective of targeted therapy for B-cell lymphoma]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801 |
| Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 korean patients. | Annals of dermatology 20110801 |
| Epigenetic treatment of neurological disease. | Epigenomics 20110801 |
| Epigenetic regulation of prostate cancer. | Clinical epigenetics 20110801 |
| Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. | Clinical epigenetics 20110801 |
| Targeting Huntington's disease through histone deacetylases. | Clinical epigenetics 20110801 |
| Epigenetic approaches in stem cell transplantation. | Clinical epigenetics 20110801 |
| Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. | Cancer letters 20110728 |
| Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. | Vaccine 20110726 |
| A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. | Bioorganic & medicinal chemistry letters 20110715 |
| Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes. | Journal of medicinal chemistry 20110714 |
| Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. | Journal of medicinal chemistry 20110714 |
| Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | Journal of medicinal chemistry 20110714 |
| Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. | Cancer gene therapy 20110701 |
| Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. | Cancer research 20110701 |
| The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. | Nuclear medicine and biology 20110701 |
| [Epigenetic therapy in myelodysplastic syndromes]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110701 |
| Efficient organic monoliths prepared by γ-radiation induced polymerization in the evaluation of histone deacetylase inhibitors by capillary(nano)-high performance liquid chromatography and ion trap mass spectrometry. | Journal of chromatography. A 20110624 |
| Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. | Bioorganic & medicinal chemistry 20110615 |
| Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs). | Bioorganic & medicinal chemistry 20110615 |
| Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110615 |
| A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. | British journal of cancer 20110607 |
| Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. | Neuropathology and applied neurobiology 20110601 |
| Leukemia cutis in association With Grover's disease. | The American Journal of dermatopathology 20110601 |
| Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. | Kidney international 20110601 |
| Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes. | Journal of inorganic biochemistry 20110601 |
| Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. | Cancer research 20110601 |
| Metabolism as a key to histone deacetylase inhibition. | Critical reviews in biochemistry and molecular biology 20110601 |
| HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells. | Molecular cancer research : MCR 20110601 |
| Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. | Oncotarget 20110601 |
| Clinical development of panobinostat in classical Hodgkin's lymphoma. | Expert review of hematology 20110601 |
| SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. | PLoS genetics 20110601 |
| Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. | Cancer research 20110515 |
| HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110515 |
| Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. | The Journal of biological chemistry 20110506 |
| Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. | Bone 20110501 |
| Discovery of histone deacetylase 8 selective inhibitors. | Bioorganic & medicinal chemistry letters 20110501 |
| Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. | The American journal of pathology 20110501 |
| Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. | Journal of medicinal chemistry 20110428 |
| Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. | Journal of medicinal chemistry 20110428 |
| Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors. | Bioorganic & medicinal chemistry letters 20110415 |
| Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110415 |
| Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation. | Journal of medicinal chemistry 20110414 |
| The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy. | Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20110401 |
| Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. | Molecular and cellular biochemistry 20110401 |
| The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. | British journal of pharmacology 20110401 |
| Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis. | Cancer science 20110401 |
| KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. | Oncology reports 20110401 |
| Differentiation of NUT midline carcinoma by epigenomic reprogramming. | Cancer research 20110401 |
| The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. | Journal of drugs in dermatology : JDD 20110401 |
| Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320 |
| Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110315 |
| Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. | British journal of cancer 20110315 |
| Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). | Cancer chemotherapy and pharmacology 20110301 |
| The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas. | Current hematologic malignancy reports 20110301 |
| Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation. | Leukemia 20110301 |
| HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. | International journal of oncology 20110301 |
| 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. | The Journal of steroid biochemistry and molecular biology 20110301 |
| Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. | British journal of cancer 20110301 |
| New drug therapies in peripheral T-cell lymphoma. | Expert review of anticancer therapy 20110301 |
| Epigenetics in cancer: what's the future? | Oncology (Williston Park, N.Y.) 20110301 |
| [Design, synthesis, and biological activities of histone deacetylase inhibitors with diketo ester as zinc binding group]. | Yao xue xue bao = Acta pharmaceutica Sinica 20110301 |
| Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. | The Journal of biological chemistry 20110225 |
| Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. | Biochemical pharmacology 20110215 |
| Histone deacetylase inhibitors as a tool to up-regulate new fungal biosynthetic products: isolation of EGM-556, a cyclodepsipeptide, from Microascus sp. | Organic letters 20110204 |
| Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. | Expert opinion on investigational drugs 20110201 |
| Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. | Future oncology (London, England) 20110201 |
| Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. | Cell death & disease 20110201 |
| Therapeutic advances in cutaneous T-cell lymphoma. | Skin therapy letter 20110201 |
| Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. | Neuron 20110127 |
| Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors. | Analytical biochemistry 20110115 |
| Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. | Biochemical and biophysical research communications 20110107 |
| Synthetic lethality: general principles, utility and detection using genetic screens in human cells. | FEBS letters 20110103 |
| Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. | Breast cancer research and treatment 20110101 |
| Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. | Molecular pharmacology 20110101 |
| Identification of clinically used drugs that activate pregnane X receptors. | Drug metabolism and disposition: the biological fate of chemicals 20110101 |
| The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients. | Advances in hematology 20110101 |
| Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. | Journal of biomedicine & biotechnology 20110101 |
| Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence. | Neoplasma 20110101 |
| Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. | Journal of biomedicine & biotechnology 20110101 |
| Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. | Journal of biomedicine & biotechnology 20110101 |
| Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. | Journal of biomedicine & biotechnology 20110101 |
| Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? | Journal of biomedicine & biotechnology 20110101 |
| Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. | Journal of biomedicine & biotechnology 20110101 |
| Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay. | Journal of biomedicine & biotechnology 20110101 |
| Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors. | Silence 20110101 |
| HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter. | Journal of biomedicine & biotechnology 20110101 |
| Finding a cure for HIV: will it ever be achievable? | Journal of the International AIDS Society 20110101 |
| Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks. | Genome integrity 20110101 |
| The role of HDACs inhibitors in childhood and adolescence acute leukemias. | Journal of biomedicine & biotechnology 20110101 |
| Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. | PloS one 20110101 |
| Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. | PloS one 20110101 |
| C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. | Cell death & disease 20110101 |
| Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. | American journal of translational research 20110101 |
| Heterogeneity in the kinetics of nuclear proteins and trajectories of substructures associated with heterochromatin. | Epigenetics & chromatin 20110101 |
| Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. | Molecular medicine (Cambridge, Mass.) 20110101 |
| HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. | PloS one 20110101 |
| Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. | Core evidence 20110101 |
| Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. | Radiation oncology (London, England) 20110101 |
| Identification of common differentially expressed genes in urinary bladder cancer. | PloS one 20110101 |
| Apoptotic sphingolipid ceramide in cancer therapy. | Journal of lipids 20110101 |
| p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. | PloS one 20110101 |
| Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. | Oncology research 20110101 |
| Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia. | Cancer management and research 20110101 |
| Selectivity of Inhibition of N-Succinyl-l,l-Diaminopimelic Acid Desuccinylase in Bacteria: The product of dapE-gene Is Not the Target of l-Captopril Antimicrobial Activity. | Bioinorganic chemistry and applications 20110101 |
| Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. | BMC neuroscience 20110101 |
| Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. | Molecular cancer 20110101 |
| Interpreting clinical assays for histone deacetylase inhibitors. | Cancer management and research 20110101 |
| Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. | Journal of biomedicine & biotechnology 20110101 |
| Myelodysplastic syndrome and histone deacetylase inhibitors: 'to be or not to be acetylated'? | Journal of biomedicine & biotechnology 20110101 |
| Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. | Core evidence 20110101 |
| Epigenetic changes in cancer. | F1000 biology reports 20110101 |
| Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. | PloS one 20110101 |
| Promising molecular targeted therapies in breast cancer. | Indian journal of pharmacology 20110101 |
| Epigenetic predictor of age. | PloS one 20110101 |
| Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. | Journal of biomedicine & biotechnology 20110101 |
| A pharmacogenomic method for individualized prediction of drug sensitivity. | Molecular systems biology 20110101 |
| Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. | Therapeutic advances in medical oncology 20110101 |
| Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. | PloS one 20110101 |
| The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells. | Cancer cell international 20110101 |
| Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. | Molecular cancer 20110101 |
| The biology of HDAC in cancer: the nuclear and epigenetic components. | Handbook of experimental pharmacology 20110101 |
| Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. | PloS one 20110101 |
| Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter. | Retrovirology 20110101 |
| The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. | PloS one 20110101 |
| Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. | PloS one 20110101 |
| Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. | Radiation oncology (London, England) 20110101 |
| Targeting HDACs: a promising therapy for Alzheimer's disease. | Oxidative medicine and cellular longevity 20110101 |
| Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. | OncoTargets and therapy 20110101 |
| Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. | Oxidative medicine and cellular longevity 20110101 |
| Promoting illiteracy in epigenetics: an emerging therapeutic strategy. | Current chemical genomics 20110101 |
| GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. | PloS one 20110101 |
| Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. | Retrovirology 20110101 |
| Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study. | BMC cancer 20110101 |
| A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. | PloS one 20110101 |
| Potential non-oncological applications of histone deacetylase inhibitors. | American journal of translational research 20110101 |
| The microenvironment in breast cancer progression: biology and implications for treatment. | Breast cancer research : BCR 20110101 |
| Epigenetics in breast cancer: what's new? | Breast cancer research : BCR 20110101 |
| Secretome Analysis of Skeletal Myogenesis Using SILAC and Shotgun Proteomics. | International journal of proteomics 20110101 |
| A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. | ISRN hematology 20110101 |
| Metastatic bladder cancer: a review of current management. | ISRN urology 20110101 |
| Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. | PloS one 20110101 |
| New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. | Prostate cancer 20110101 |
| SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. | PloS one 20110101 |
| Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. | Journal of translational medicine 20110101 |
| Epigenetics in prostate cancer. | Prostate cancer 20110101 |
| Molecular mechanisms of bortezomib resistant adenocarcinoma cells. | PloS one 20110101 |
| Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. | Clinical epigenetics 20110101 |
| Romidepsin in the treatment of cutaneous T-cell lymphoma. | Journal of blood medicine 20110101 |
| An update on the management of peripheral T-cell lymphoma and emerging treatment options. | Journal of blood medicine 20110101 |
| Autophagy: friend or foe in breast cancer development, progression, and treatment. | International journal of breast cancer 20110101 |
| The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone. | International journal of breast cancer 20110101 |
| In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC). | BMC bioinformatics 20110101 |
| Suffocating cancer: hypoxia-associated epimutations as targets for cancer therapy. | Clinical epigenetics 20110101 |
| Cell death signaling and anticancer therapy. | Frontiers in oncology 20110101 |
| Investigational approaches for mesothelioma. | Frontiers in oncology 20110101 |
| Ocular manifestations and pathology of adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus type 1. | Rare tumors 20101231 |
| Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. | Blood 20101223 |
| Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. | Journal of medicinal chemistry 20101223 |
| Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. | Journal of medicinal chemistry 20101223 |
| Discovery of 1H-benzo[d][1,2,3]triazol-1-yl 3,4,5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase. | Bioorganic & medicinal chemistry 20101215 |
| Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. | Investigational new drugs 20101201 |
| Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. | The pharmacogenomics journal 20101201 |
| Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. | Journal of cancer research and clinical oncology 20101201 |
| Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. | Annals of surgical oncology 20101201 |
| Autophagy and tumorigenesis. | Seminars in immunopathology 20101201 |
| A novel xenograft model of cutaneous T-cell lymphoma. | Experimental dermatology 20101201 |
| Inhibition of class IIb histone deacetylase significantly improves cloning efficiency in mice. | Biology of reproduction 20101201 |
| Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. | Gynecologic oncology 20101201 |
| Inhibitors selective for HDAC6 in enzymes and cells. | Bioorganic & medicinal chemistry letters 20101201 |
| Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. | The EMBO journal 20101201 |
| The DAC system and associations with multiple myeloma. | Investigational new drugs 20101201 |
| Deactylase inhibition in myeloproliferative neoplasms. | Investigational new drugs 20101201 |
| Histone deacetylase inhibitors in Hodgkin lymphoma. | Investigational new drugs 20101201 |
| Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. | Investigational new drugs 20101201 |
| The DAC system and associations with acute leukemias and myelodysplastic syndromes. | Investigational new drugs 20101201 |
| The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. | Molecular cancer therapeutics 20101201 |
| Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. | Molecular cancer therapeutics 20101201 |
| Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. | Investigational new drugs 20101201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20101201 |
| Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells. | Bioorganic & medicinal chemistry letters 20101115 |
| Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases. | Bioorganic & medicinal chemistry letters 20101115 |
| Poikilodermatous mycosis fungoides. | Dermatology online journal 20101115 |
| Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. | British journal of cancer 20101109 |
| Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. | Journal of cellular physiology 20101101 |
| Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. | Pancreas 20101101 |
| Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. | Annals of hematology 20101101 |
| HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. | Cancer letters 20101101 |
| In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? | Gynecologic oncology 20101101 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. | Cancer chemotherapy and pharmacology 20101101 |
| A histone deacetylase-dependent screen in yeast. | Bioorganic & medicinal chemistry 20101101 |
| Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA. | Oncology reports 20101101 |
| Synergistic killing effect between vorinostat and target of CD146 in malignant cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101101 |
| Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. | Autophagy 20101101 |
| Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line. | Experimental biology and medicine (Maywood, N.J.) 20101101 |
| Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. | British journal of cancer 20101101 |
| Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. | British journal of cancer 20101026 |
| Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. | Blood 20101021 |
| Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. | Blood 20101014 |
| Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. | Oncogene 20101014 |
| Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101010 |
| Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. | Journal of cellular and molecular medicine 20101001 |
| Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. | Apoptosis : an international journal on programmed cell death 20101001 |
| Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. | Brain research 20101001 |
| Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. | Anti-cancer drugs 20101001 |
| The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. | British journal of haematology 20101001 |
| Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. | Molecular cancer therapeutics 20101001 |
| The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. | Autophagy 20101001 |
| A pharmacogenetic study of vorinostat glucuronidation. | Pharmacogenetics and genomics 20101001 |
| Solubilization of vorinostat by cyclodextrins. | Journal of clinical pharmacy and therapeutics 20101001 |
| Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. | Aging 20101001 |
| HDAC pharmacological inhibition promotes cell death through the eIF2α kinases PKR and GCN2. | Aging 20101001 |
| Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. | Cancer letters 20100928 |
| Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. | Journal of neuro-oncology 20100901 |
| Identification of type-specific anticancer histone deacetylase inhibitors: road to success. | Cancer chemotherapy and pharmacology 20100901 |
| Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures. | Biomaterials 20100901 |
| Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock. | The Journal of surgical research 20100901 |
| Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. | Urology 20100901 |
| Design and synthesis of novel isoxazole-based HDAC inhibitors. | European journal of medicinal chemistry 20100901 |
| Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. | International journal of radiation oncology, biology, physics 20100901 |
| Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. | Expert opinion on investigational drugs 20100901 |
| Histone deacetylase inhibitors in lymphoma. | Current opinion in oncology 20100901 |
| Drug-induced regulation of target expression. | PLoS computational biology 20100901 |
| [Development of HDAC inhibitors]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100901 |
| Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. | Journal of medicinal chemistry 20100826 |
| Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820 |
| Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. | Proceedings of the National Academy of Sciences of the United States of America 20100817 |
| A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor. | The Journal of biological chemistry 20100813 |
| A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors. | ChemMedChem 20100802 |
| Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. | The Journal of clinical investigation 20100802 |
| The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. | Cancer chemotherapy and pharmacology 20100801 |
| Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. | Rheumatology (Oxford, England) 20100801 |
| The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100801 |
| Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. | Autophagy 20100801 |
| Surviving lethal septic shock without fluid resuscitation in a rodent model. | Surgery 20100801 |
| Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells. | International journal of oncology 20100801 |
| Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801 |
| Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. | Cancer research 20100801 |
| Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. | Cancer prevention research (Philadelphia, Pa.) 20100801 |
| Serine proteases in histone deacetylase inhibitor-induced apoptosis. | Molecular cancer therapeutics 20100801 |
| Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. | Molecular cancer therapeutics 20100801 |
| An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with mitomycin-C and a histone deacetylase inhibitor. | Archives of pharmacal research 20100801 |
| A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100715 |
| The functional significance of microRNA-145 in prostate cancer. | British journal of cancer 20100713 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. | Haematologica 20100701 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. | Cardiovascular research 20100701 |
| A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. | British journal of haematology 20100701 |
| Targeted treatment and new agents in peripheral T-cell lymphoma. | International journal of hematology 20100701 |
| Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. | Bioorganic & medicinal chemistry letters 20100701 |
| A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. | British journal of cancer 20100629 |
| Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. | Cancer letters 20100628 |
| Probing the probes: fitness factors for small molecule tools. | Chemistry & biology 20100625 |
| Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. | Journal of medicinal chemistry 20100624 |
| Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function . | Biochemistry 20100622 |
| New aryldithiolethione derivatives as potent histone deacetylase inhibitors. | Bioorganic & medicinal chemistry 20100615 |
| The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. | Blood 20100603 |
| Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. | Journal of leukocyte biology 20100601 |
| Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). | Pharmaceutical research 20100601 |
| Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. | Cancer science 20100601 |
| Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. | Bioorganic & medicinal chemistry letters 20100601 |
| Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids. | Bioorganic & medicinal chemistry 20100601 |
| Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. | Cancer research 20100601 |
| Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. | Cancer 20100601 |
| Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene. | Cell cycle (Georgetown, Tex.) 20100601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100601 |
| Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. | Current treatment options in oncology 20100601 |
| Targeting histone deacetylases: development of vorinostat for the treatment of cancer. | Epigenomics 20100601 |
| AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. | Blood 20100527 |
| Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. | International journal of cancer 20100515 |
| Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. | Bioorganic & medicinal chemistry letters 20100515 |
| Synthesis and anticancer evaluation of alpha-lipoic acid derivatives. | Bioorganic & medicinal chemistry letters 20100515 |
| Histone deacetylase inhibitors: Are they here to stay? | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100515 |
| Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100515 |
| Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease. | Neuroscience letters 20100514 |
| Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. | The Lancet. Oncology 20100501 |
| Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. | The Journal of thoracic and cardiovascular surgery 20100501 |
| [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors]. | Pharmazie in unserer Zeit 20100501 |
| SAHA and curcumin combinations co-enhance histone acetylation in human cancer cells but operate antagonistically in exerting cytotoxic effects. | Journal of Asian natural products research 20100501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100501 |
| Diagnosis and management of mycosis fungoides. | Oncology (Williston Park, N.Y.) 20100501 |
| [Three different drug interaction mathematical models used to evaluate the cytotoxicity of SAHA and arsenic trioxide in combination]. | Yao xue xue bao = Acta pharmaceutica Sinica 20100501 |
| Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. | Journal of medicinal chemistry 20100422 |
| SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. | Human molecular genetics 20100415 |
| Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100415 |
| Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase. | ChemMedChem 20100406 |
| Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. | Breast cancer research and treatment 20100401 |
| Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. | International journal of cancer 20100401 |
| A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. | Cancer chemotherapy and pharmacology 20100401 |
| Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. | Haematologica 20100401 |
| Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. | British journal of pharmacology 20100401 |
| Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. | International journal of oncology 20100401 |
| The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. | Clinical lymphoma, myeloma & leukemia 20100401 |
| Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. | Clinical lymphoma, myeloma & leukemia 20100401 |
| Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. | Expert review of hematology 20100401 |
| The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. | Blood 20100325 |
| SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20100315 |
| Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. | Journal of medicinal chemistry 20100311 |
| Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring. | Journal of medicinal chemistry 20100311 |
| Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation. | Molecular therapy : the journal of the American Society of Gene Therapy 20100301 |
| Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. | European journal of haematology 20100301 |
| Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100301 |
| Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100301 |
| The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. | Cellular and molecular life sciences : CMLS 20100301 |
| Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. | Proteomics 20100301 |
| Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. | Leukemia 20100301 |
| Chemical phylogenetics of histone deacetylases. | Nature chemical biology 20100301 |
| Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. | Bioorganic & medicinal chemistry 20100301 |
| SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. | Molecular cancer therapeutics 20100301 |
| Current and emerging treatment strategies for cutaneous T-cell lymphoma. | Drugs 20100212 |
| Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. | Journal of medicinal chemistry 20100211 |
| Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. | International journal of cancer 20100201 |
| Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. | American journal of physiology. Renal physiology 20100201 |
| Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. | The Journal of clinical endocrinology and metabolism 20100201 |
| Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100201 |
| Suberoylanilide hydroxyamic acid modification of chromatin architecture affects DNA break formation and repair. | International journal of radiation oncology, biology, physics 20100201 |
| HDAC inhibitors in cancer care. | Oncology (Williston Park, N.Y.) 20100201 |
| Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. | Epigenomics 20100201 |
| Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. | Chemistry & biology 20100129 |
| Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. | Journal of medicinal chemistry 20100128 |
| Fluoroalkene modification of mercaptoacetamide-based histone deacetylase inhibitors. | Bioorganic & medicinal chemistry 20100115 |
| Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. | Oncogene 20100107 |
| Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. | Cancer science 20100101 |
| Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. | Gynecologic oncology 20100101 |
| Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. | International journal of toxicology 20100101 |
| Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. | Journal of cellular biochemistry 20100101 |
| Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. | Bioorganic & medicinal chemistry 20100101 |
| Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100101 |
| HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity. | Oncology reports 20100101 |
| Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. | Nature chemical biology 20100101 |
| Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100101 |
| Histone deacetylase inhibitor therapy in epithelial ovarian cancer. | Journal of oncology 20100101 |
| The saving switch. | Nature medicine 20100101 |
| Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. | Neoplasia (New York, N.Y.) 20100101 |
| Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. | PloS one 20100101 |
| Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. | Journal of hematology & oncology 20100101 |
| EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. | Molecular cancer 20100101 |
| PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. | International journal of cell biology 20100101 |
| Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. | International journal of cell biology 20100101 |
| Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. | Obstetrics and gynecology international 20100101 |
| BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer. | Journal of oncology 20100101 |
| Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. | PloS one 20100101 |
| Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. | Molecular cancer 20100101 |
| Response to hydralazine-valproate in a patient with mycosis fungoides. | Case reports in medicine 20100101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. | Journal of oncology 20100101 |
| Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. | Journal of hematology & oncology 20100101 |
| Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice. | BMC molecular biology 20100101 |
| Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. | Journal of hematology & oncology 20100101 |
| Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides. | Marine drugs 20100101 |
| Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. | PloS one 20100101 |
| The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. | PloS one 20100101 |
| Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. | Journal of translational medicine 20100101 |
| Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. | PloS one 20100101 |
| Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. | PloS one 20100101 |
| An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. | OncoTargets and therapy 20100101 |
| Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. | PloS one 20100101 |
| Molecular and therapeutic potential and toxicity of valproic acid. | Journal of biomedicine & biotechnology 20100101 |
| Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination. | Cancer cell international 20100101 |
| Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. | Journal of biomedical science 20100101 |
| Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine. | OncoTargets and therapy 20100101 |
| A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. | PloS one 20100101 |
| Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor. | Molecular cancer 20100101 |
| Oral systemic therapy: Not all 'win-win'. | Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101 |
| Safety and efficacy of azacitidine in myelodysplastic syndromes. | Drug design, development and therapy 20100101 |
| Dietary, metabolic, and potentially environmental modulation of the lysine acetylation machinery. | International journal of cell biology 20100101 |
| Targeted therapy in lymphoma. | Journal of hematology & oncology 20100101 |
| Proteasome inhibition and its therapeutic potential in multiple myeloma. | Biologics : targets & therapy 20100101 |
| Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. | PloS one 20100101 |
| Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. | Proteomics. Clinical applications 20100101 |
| Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma. | Cancer management and research 20100101 |
| An update in management of noncutaneous T-cell lymphomas. | Advances in hematology 20100101 |
| CoFactor: Folate Requirement for Optimization of 5-Fluouracil Activity in Anticancer Chemotherapy. | Journal of oncology 20100101 |
| Peripheral T-cell lymphoma: review and updates of current management strategies. | Advances in hematology 20100101 |
| Relapsed multiple myeloma. | Hematology. American Society of Hematology. Education Program 20100101 |
| Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. | PloS one 20100101 |
| New treatments for myelodysplastic syndromes. | Mediterranean journal of hematology and infectious diseases 20100101 |
| Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. | Molecular medicine reports 20100101 |
| A putrescine-anthracene conjugate: a paradigm for selective drug delivery. | The Biochemical journal 20091215 |
| Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. | Cancer 20091201 |
| HTS and hit finding in academia--from chemical genomics to drug discovery. | Drug discovery today 20091201 |
| Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide. | Bioorganic & medicinal chemistry letters 20091201 |
| MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. | International journal of oncology 20091201 |
| Molecular targets in malignant pleural mesothelioma treatment. | Current drug targets 20091201 |
| Emerging treatment combinations: integrating therapy into clinical practice. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091201 |
| New patented histone deacetylase inhibitors. | Expert opinion on therapeutic patents 20091201 |
| Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. | Clinical lymphoma & myeloma 20091201 |
| Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201 |
| New treatment strategy enhances outcome for lung cancer. | Cancer biology & therapy 20091201 |
| A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091115 |
| Hydroxamates: relationships between structure and plasma stability. | Journal of medicinal chemistry 20091112 |
| Histone deacetylase inhibitors in cancer therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110 |
| Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. | Cancer chemotherapy and pharmacology 20091101 |
| Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. | Shock (Augusta, Ga.) 20091101 |
| Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. | Journal of neuro-oncology 20091101 |
| Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. | Molecular and biochemical parasitology 20091101 |
| Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. | European journal of medicinal chemistry 20091101 |
| Pathway targets to explore in the treatment of small cell and large cell lung cancers. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091101 |
| Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. | European journal of cancer (Oxford, England : 1990) 20091101 |
| Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. | Molecular cancer therapeutics 20091101 |
| Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach. | Molecular cancer therapeutics 20091101 |
| Leukonychia related to vorinostat. | Archives of dermatology 20091101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091101 |
| Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene. | Journal of molecular biology 20091023 |
| Suberoylanilide hydroxamic acid promotes cardiomyocyte differentiation of rat mesenchymal stem cells. | Experimental cell research 20091015 |
| Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor. | Journal of medicinal chemistry 20091008 |
| Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. | British journal of cancer 20091006 |
| Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. | The Journal of pharmacology and experimental therapeutics 20091001 |
| Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line. | Leukemia 20091001 |
| A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. | Anti-cancer drugs 20091001 |
| Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20091001 |
| Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| A phase 2 study of vorinostat in acute myeloid leukemia. | Haematologica 20091001 |
| Antidepressant actions of histone deacetylase inhibitors. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20090916 |
| SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells. | Chemico-biological interactions 20090914 |
| Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. | Oncogene 20090903 |
| Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. | Breast cancer research and treatment 20090901 |
| Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. | Oral oncology 20090901 |
| Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. | Investigative ophthalmology & visual science 20090901 |
| Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. | Pediatric blood & cancer 20090901 |
| Chemical induction of silent biosynthetic pathway transcription in Aspergillus niger. | Journal of industrial microbiology & biotechnology 20090901 |
| KLF4 suppresses HDACi induced caspase activation and the SAPK pathway by targeting p57(Kip2). | Apoptosis : an international journal on programmed cell death 20090901 |
| Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. | Cancer science 20090901 |
| MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. | International journal of oncology 20090901 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. | AIDS research and human retroviruses 20090901 |
| Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. | Cancer research 20090901 |
| Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. | Molecular cancer therapeutics 20090901 |
| Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma. | Archives of dermatology 20090901 |
| The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation. | Free radical biology & medicine 20090815 |
| Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. | Cancer research 20090815 |
| Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090815 |
| Lysine acetylation targets protein complexes and co-regulates major cellular functions. | Science (New York, N.Y.) 20090814 |
| Recent advances in the development of polyamine analogues as antitumor agents. | Journal of medicinal chemistry 20090813 |
| MeCP2 function in the basolateral amygdala in Rett syndrome. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20090812 |
| Development of vorinostat: current applications and future perspectives for cancer therapy. | Cancer letters 20090808 |
| HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy. | Cancer letters 20090808 |
| Histone deacetylase inhibitors as anti-neoplastic agents. | Cancer letters 20090808 |
| Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. | Cancer letters 20090808 |
| The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. | Leukemia 20090801 |
| Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. | Molecular pharmacology 20090801 |
| BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. | Molecular pharmacology 20090801 |
| HDAC inhibitor-based therapies and haematological malignancy. | Annals of oncology : official journal of the European Society for Medical Oncology 20090801 |
| Histone modifier, the gatekeeper of good memory. | Cell research 20090801 |
| In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. | Anticancer research 20090801 |
| Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. | International journal of cancer 20090715 |
| Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. | Bioorganic & medicinal chemistry 20090715 |
| Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. | Annals of hematology 20090701 |
| Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? | The European respiratory journal 20090701 |
| Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. | Current opinion in hematology 20090701 |
| Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. | Cancer biology & therapy 20090701 |
| Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. | Cancer biology & therapy 20090701 |
| Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer. | Cancer biology & therapy 20090701 |
| Histone deacetylase inhibitors: Potential in cancer therapy. | Journal of cellular biochemistry 20090701 |
| Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. | International journal of molecular medicine 20090701 |
| A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome. | Journal of the American Academy of Dermatology 20090701 |
| Clinical roundtable monograph. Combination therapies for MDS. | Clinical advances in hematology & oncology : H&O 20090701 |
| Epigenetic modifiers: basic understanding and clinical development. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Clinical studies of histone deacetylase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. | Journal of medicinal chemistry 20090611 |
| Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice. | Cancer chemotherapy and pharmacology 20090601 |
| An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes. | International journal for parasitology 20090601 |
| Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. | European journal of haematology 20090601 |
| Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells. | Endocrine 20090601 |
| Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. | Anti-cancer drugs 20090601 |
| Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. | Bioorganic & medicinal chemistry letters 20090601 |
| Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. | Bioorganic & medicinal chemistry letters 20090601 |
| Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. | International journal of radiation oncology, biology, physics 20090601 |
| Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090601 |
| American Association for Cancer Research 100th Annual Meeting. | The Lancet. Oncology 20090601 |
| Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. | Molecular cancer therapeutics 20090601 |
| Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. | Molecular cancer therapeutics 20090601 |
| Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. | Bioorganic & medicinal chemistry letters 20090515 |
| Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases. | Journal of medicinal chemistry 20090514 |
| Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. | Journal of medicinal chemistry 20090514 |
| HDAC2 negatively regulates memory formation and synaptic plasticity. | Nature 20090507 |
| Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. | Stem cells and development 20090501 |
| Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. | European journal of medicinal chemistry 20090501 |
| Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. | Molecular pharmacology 20090501 |
| Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. | Cancer biology & therapy 20090501 |
| Efficient continuous flow synthesis of hydroxamic acids and suberoylanilide hydroxamic acid preparation. | The Journal of organic chemistry 20090501 |
| A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090501 |
| Targeted therapies for renal cell carcinoma: more gains from using them again. | Current oncology (Toronto, Ont.) 20090501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090501 |
| Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. | Blood 20090430 |
| Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. | Blood 20090423 |
| Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. | Journal of medicinal chemistry 20090423 |
| Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. | Journal of medicinal chemistry 20090423 |
| Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090420 |
| Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090415 |
| Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. | The international journal of biochemistry & cell biology 20090401 |
| ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). | Annals of oncology : official journal of the European Society for Medical Oncology 20090401 |
| Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. | Cancer research 20090401 |
| Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. | Nuclear medicine and biology 20090401 |
| Variations in c-Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death. | Cell biochemistry and function 20090401 |
| Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. | Technology in cancer research & treatment 20090401 |
| MeCP2-mediated transcription repression in the basolateral amygdala may underlie heightened anxiety in a mouse model of Rett syndrome. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20090401 |
| Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090401 |
| A kernel for open source drug discovery in tropical diseases. | PLoS neglected tropical diseases 20090401 |
| Regulation of adipocyte differentiation by histone deacetylase inhibitors. | Archives of pharmacal research 20090401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090401 |
| HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. | The Journal of biological chemistry 20090320 |
| Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity. | Oncogene 20090319 |
| Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. | Bioorganic & medicinal chemistry 20090315 |
| Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. | The Journal of biological chemistry 20090313 |
| Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells. | Arteriosclerosis, thrombosis, and vascular biology 20090301 |
| Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. | Carcinogenesis 20090301 |
| Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090301 |
| Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. | Blood 20090226 |
| Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. | International journal of cancer 20090215 |
| Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. | Molecular cancer therapeutics 20090201 |
| Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. | AIDS research and human retroviruses 20090201 |
| The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application. | Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20090201 |
| High-throughput screening compatible cell-based assay for interrogating activated notch signaling. | Assay and drug development technologies 20090201 |
| Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. | Human molecular genetics 20090115 |
| Sulfamides as novel histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20090115 |
| Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090115 |
| A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. | British journal of cancer 20090113 |
| Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. | The Journal of clinical endocrinology and metabolism 20090101 |
| Structure-activity relationship studies of novel oxygen-incorporated SAHA analogues. | Archives of pharmacal research 20090101 |
| Targeting histone deacetylases in neuroblastoma. | Current pharmaceutical design 20090101 |
| Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. | Molecular cancer 20090101 |
| Toxicity of targeted therapy in non-small-cell lung cancer management. | Clinical lung cancer 20090101 |
| Assays for histone deacetylases. | Current topics in medicinal chemistry 20090101 |
| Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies. | Current topics in medicinal chemistry 20090101 |
| Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. | Cellular immunology 20090101 |
| New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. | Journal of hematology & oncology 20090101 |
| 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. | Retrovirology 20090101 |
| Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. | PloS one 20090101 |
| Vorinostat in solid and hematologic malignancies. | Journal of hematology & oncology 20090101 |
| Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. | PloS one 20090101 |
| Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. | PloS one 20090101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090101 |
| Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. | Molecular cancer 20090101 |
| High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. | BMC cancer 20090101 |
| DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. | BMC medical genomics 20090101 |
| Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. | Retrovirology 20090101 |
| Managing myelodysplastic symptoms in elderly patients. | Clinical interventions in aging 20090101 |
| Targeted therapy in the treatment of malignant gliomas. | OncoTargets and therapy 20090101 |
| Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. | Core evidence 20090101 |
| Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction. | International immunopharmacology 20081220 |
| Histone deacetylase inhibitors through click chemistry. | Journal of medicinal chemistry 20081211 |
| HDAC inhibition upregulates the expression of angiostatic ADAMTS1. | FEBS letters 20081210 |
| Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. | Cancer letters 20081208 |
| Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. | Journal of leukocyte biology 20081201 |
| Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. | Nature clinical practice. Oncology 20081201 |
| SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. | The Journal of pathology 20081201 |
| Molecular biology and targeted therapy of cutaneous T-cell lymphomas. | Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 20081201 |
| Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid. | Journal of biosciences 20081201 |
| Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. | Biologics : targets & therapy 20081201 |
| Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. | Journal of medicinal chemistry 20081127 |
| Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. | Breast cancer research and treatment 20081101 |
| Sensitization of RPE cells by alphaB-crystallin siRNA to SAHA-induced stage 1 apoptosis through abolishing the association of alphaB-crystallin with HDAC1 in SC35 speckles. | Investigative ophthalmology & visual science 20081101 |
| A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081101 |
| A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081101 |
| Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors. | Proteins 20081001 |
| The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. | Critical reviews in oncology/hematology 20081001 |
| Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. | Investigational new drugs 20081001 |
| Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. | Blood 20081001 |
| Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. | Blood 20081001 |
| HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. | Biochimica et biophysica acta 20081001 |
| Regulation of autophagy by ceramide-CD95-PERK signaling. | Autophagy 20081001 |
| Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. | Cancer biology & therapy 20081001 |
| Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. | Cancer biology & therapy 20081001 |
| Treatment of cutaneous T-cell lymphoma: focus on vorinostat. | Journal of the American Academy of Dermatology 20081001 |
| Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. | Cancer control : journal of the Moffitt Cancer Center 20081001 |
| Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). | International journal of oncology 20081001 |
| Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081001 |
| [Epigenetics in hematological disorders]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001 |
| Histone deacetylase inhibitors as novel anticancer therapeutics. | Current oncology (Toronto, Ont.) 20081001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20081001 |
| Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. | Bioorganic & medicinal chemistry letters 20080915 |
| Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? | British journal of cancer 20080902 |
| Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. | ChemMedChem 20080901 |
| In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. | International journal of pharmaceutics 20080901 |
| Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. | Annals of surgical oncology 20080901 |
| Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. | Histopathology 20080901 |
| Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. | Cancer biology & therapy 20080901 |
| Recent advances in the treatment of malignant pleural mesothelioma. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080901 |
| Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080901 |
| Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. | Journal of the American Chemical Society 20080820 |
| Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. | Blood 20080815 |
| Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. | Journal of medicinal chemistry 20080814 |
| Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. | Blood 20080801 |
| The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. | International journal of oncology 20080801 |
| Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. | Surgery 20080801 |
| Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. | Cancer science 20080801 |
| Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. | Oncogene 20080724 |
| Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses. | Statistics in medicine 20080720 |
| Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles. | Journal of medicinal chemistry 20080710 |
| Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells. | Journal of proteome research 20080701 |
| Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. | The Journal of clinical investigation 20080701 |
| Isoform-selective histone deacetylase inhibitors. | Chemical Society reviews 20080701 |
| Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. | Oncology reports 20080701 |
| Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. | American journal of veterinary research 20080701 |
| Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. | Molecular cancer therapeutics 20080701 |
| Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080701 |
| Targeted treatment and new agents in diffuse large B-cell lymphoma. | Seminars in hematology 20080701 |
| A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. | Journal of medicinal chemistry 20080626 |
| Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. | The Journal of pharmacology and experimental therapeutics 20080601 |
| Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. | Current medicinal chemistry 20080601 |
| Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. | Biologics : targets & therapy 20080601 |
| The use of diversity profiling to characterize chemical modulators of the histone deacetylases. | Life sciences 20080523 |
| Structural origin of selectivity in class II-selective histone deacetylase inhibitors. | Journal of medicinal chemistry 20080522 |
| Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. | Cancer research 20080515 |
| OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. | Cancer research 20080515 |
| Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080515 |
| Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. | Gut 20080501 |
| A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. | Gynecologic oncology 20080501 |
| Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20080501 |
| Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. | Biochemical pharmacology 20080501 |
| Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. | Bioorganic & medicinal chemistry 20080501 |
| Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. | Bioorganic & medicinal chemistry letters 20080501 |
| Monitoring the effect of belinostat in solid tumors by H4 acetylation. | APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20080501 |
| KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. | Molecular cancer therapeutics 20080501 |
| Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. | Molecular cancer therapeutics 20080501 |
| Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. | Molecular cancer therapeutics 20080501 |
| Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. | Journal of the American Academy of Dermatology 20080501 |
| Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors. | Journal of medicinal chemistry 20080424 |
| Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. | Bioorganic & medicinal chemistry letters 20080415 |
| Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. | Cancer chemotherapy and pharmacology 20080401 |
| Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). | Journal of neuro-oncology 20080401 |
| Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. | Experimental hematology 20080401 |
| Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. | Cancer research 20080401 |
| Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. | Neoplasia (New York, N.Y.) 20080401 |
| MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. | Molecular cancer therapeutics 20080401 |
| HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. | Proceedings of the National Academy of Sciences of the United States of America 20080325 |
| Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. | Bioorganic & medicinal chemistry 20080315 |
| Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. | Bioorganic & medicinal chemistry letters 20080315 |
| Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. | Journal of medicinal chemistry 20080313 |
| Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. | Leukemia 20080301 |
| Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. | Molecular pharmacology 20080301 |
| Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. | Haematologica 20080301 |
| Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. | Leukemia & lymphoma 20080301 |
| Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery. | Current eye research 20080301 |
| Histone deacetylase inhibitors in lymphoma and solid malignancies. | Expert review of anticancer therapy 20080301 |
| Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques. | Transplantation proceedings 20080301 |
| Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. | Journal of the American Chemical Society 20080220 |
| Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080215 |
| Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. | Leukemia research 20080201 |
| Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. | Investigational new drugs 20080201 |
| Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. | Blood 20080201 |
| Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. | European journal of haematology 20080201 |
| Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor. | Birth defects research. Part B, Developmental and reproductive toxicology 20080201 |
| Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. | The Biochemical journal 20080115 |
| Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. | The international journal of biochemistry & cell biology 20080101 |
| Amino acid derivatives as histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20080101 |
| Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. | International journal of oncology 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080101 |
| EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. | PloS one 20080101 |
| A simple and robust method for connecting small-molecule drugs using gene-expression signatures. | BMC bioinformatics 20080101 |
| Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. | Molecular cancer 20080101 |
| Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. | Journal of hematology & oncology 20080101 |
| Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. | Anticancer research 20080101 |
| Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. | Anticancer research 20080101 |
| FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. | Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20080101 |
| Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. | Molecular cancer 20080101 |
| Gateways to clinical trials. July-August 2008. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? | Arthritis research & therapy 20080101 |
| Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. | Journal of ovarian research 20080101 |
| Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. | BMC cancer 20080101 |
| A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma. | Clinical medicine. Oncology 20080101 |
| Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. | Journal of medicinal chemistry 20071227 |
| Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071215 |
| Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. | Immunology 20071201 |
| Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. | Experimental hematology 20071201 |
| Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. | International journal of oncology 20071201 |
| Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells. | Endocrine-related cancer 20071201 |
| Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET. | Cancer research 20071201 |
| Epigenetic regulation as a new target for breast cancer therapy. | Cancer investigation 20071201 |
| Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. | Molecular cancer therapeutics 20071201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071201 |
| Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. | Biologics : targets & therapy 20071201 |
| Targeted therapies in the management of metastatic bladder cancer. | Biologics : targets & therapy 20071201 |
| R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. | British journal of cancer 20071119 |
| Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. | Bioorganic & medicinal chemistry letters 20071115 |
| Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. | Bioorganic & medicinal chemistry letters 20071115 |
| Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors. | Bioorganic & medicinal chemistry letters 20071115 |
| The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. | Journal of medicinal chemistry 20071115 |
| Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. | Neuron 20071108 |
| Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. | Journal of cancer research and clinical oncology 20071101 |
| Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. | Molecular cancer therapeutics 20071101 |
| Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. | Molecular cancer therapeutics 20071101 |
| Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. | Blood 20071001 |
| Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. | Hepatology (Baltimore, Md.) 20071001 |
| Comment on developmental toxicity evaluation on Vorinostat and relationship with HDAC inhibition. | Birth defects research. Part B, Developmental and reproductive toxicology 20071001 |
| Histone deacetylase inhibitor-induced glycodelin enhances the initial step of implantation. | Human reproduction (Oxford, England) 20071001 |
| Epigenetic alterations and cancer: new targets for therapy. | IDrugs : the investigational drugs journal 20071001 |
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. | The oncologist 20071001 |
| Histone deacetylase inhibitors. | Oncology (Williston Park, N.Y.) 20071001 |
| 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors. | Journal of medicinal chemistry 20070906 |
| HDAC inhibitors: clinical update and mechanism-based potential. | Biochemical pharmacology 20070901 |
| Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. | Bioorganic & medicinal chemistry letters 20070901 |
| Trithiocarbonates: exploration of a new head group for HDAC inhibitors. | Bioorganic & medicinal chemistry letters 20070901 |
| Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. | Bioorganic & medicinal chemistry letters 20070901 |
| The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. | International journal of oncology 20070901 |
| Histone deacetylase inhibitors selectively suppress expression of HDAC7. | Molecular cancer therapeutics 20070901 |
| Vorinostat in cutaneous T-cell lymphoma. | Drugs of today (Barcelona, Spain : 1998) 20070901 |
| Design of novel histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20070815 |
| Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070815 |
| Histone deacetylase inhibitors: molecular mechanisms of action. | Oncogene 20070813 |
| Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. | International journal of cancer 20070801 |
| Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. | Cell death and differentiation 20070801 |
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070720 |
| Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. | Bioorganic & medicinal chemistry letters 20070715 |
| Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070715 |
| Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. | Journal of neuro-oncology 20070701 |
| SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. | Apoptosis : an international journal on programmed cell death 20070701 |
| Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. | Blood 20070701 |
| Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. | Expert opinion on investigational drugs 20070701 |
| A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. | Journal of drugs in dermatology : JDD 20070701 |
| Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. | Biochemical pharmacology 20070615 |
| Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070615 |
| Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. | Applied microbiology and biotechnology 20070601 |
| Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. | The journal of gene medicine 20070601 |
| Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. | International journal of oncology 20070601 |
| Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. | Surgery 20070601 |
| Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. | The Journal of parasitology 20070601 |
| Bispyridinium dienes: histone deacetylase inhibitors with selective activities. | Journal of medicinal chemistry 20070517 |
| Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. | Bioorganic & medicinal chemistry letters 20070515 |
| Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. | Cancer 20070515 |
| Discovery of epigenetically silenced genes in acute myeloid leukemias. | Leukemia 20070501 |
| Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. | Cancer biology & therapy 20070501 |
| Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. | International journal of oncology 20070501 |
| In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species. | Biological & pharmaceutical bulletin 20070501 |
| Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. | Bioorganic & medicinal chemistry letters 20070415 |
| Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070415 |
| Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. | FEBS letters 20070403 |
| Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. | Biochemical pharmacology 20070401 |
| Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. | British journal of pharmacology 20070401 |
| Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. | Molecular cancer therapeutics 20070401 |
| Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. | Haematologica 20070401 |
| [Histone deacetylase inhibitor SAHA induces inactivation of MAPK signaling and apoptosis in HL-60 cells]. | Zhongguo shi yan xue ye xue za zhi 20070401 |
| Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species. | Drug metabolism letters 20070401 |
| Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20070328 |
| Vorinostat (Zolinza) for cutaneous T-Cell lymphoma. | The Medical letter on drugs and therapeutics 20070312 |
| In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. | Gynecologic oncology 20070301 |
| Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. | Bioorganic & medicinal chemistry letters 20070301 |
| Discovery and development of SAHA as an anticancer agent. | Oncogene 20070226 |
| Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy. | Bioorganic & medicinal chemistry letters 20070215 |
| Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. | Endocrinology 20070201 |
| Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. | Leukemia 20070201 |
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070201 |
| Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. | Birth defects research. Part B, Developmental and reproductive toxicology 20070201 |
| Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. | Molecular cancer therapeutics 20070201 |
| Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. | Oncology (Williston Park, N.Y.) 20070201 |
| Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. | Bioorganic & medicinal chemistry letters 20070115 |
| Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. | Bioorganic & medicinal chemistry letters 20070115 |
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). | Blood 20070101 |
| Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. | Scandinavian journal of gastroenterology 20070101 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070101 |
| HDAC inhibitors overcome first hurdle. | Nature biotechnology 20070101 |
| Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. | Nature biotechnology 20070101 |
| Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. | Molecular cancer therapeutics 20070101 |
| Vorinostat. | Nature reviews. Drug discovery 20070101 |
| c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. | The international journal of biochemistry & cell biology 20070101 |
| New skin cancer drug. | FDA consumer 20070101 |
| Modulating autophagy for therapeutic benefit. | Autophagy 20070101 |
| HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. | The international journal of biochemistry & cell biology 20070101 |
| Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells. | The international journal of biochemistry & cell biology 20070101 |
| The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. | Journal of translational medicine 20070101 |
| Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. | Molecular pharmacology 20061201 |
| A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061201 |
| Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. | Molecular cancer therapeutics 20061201 |
| Treatment of cutaneous T-cell lymphoma/mycosis fungoides. | Dermatology nursing 20061201 |
| Stability studies of vorinostat and its two metabolites in human plasma, serum and urine. | Journal of pharmaceutical and biomedical analysis 20061116 |
| Vorinostat approved for rare lymphoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061115 |
| Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells. | Oncology reports 20061101 |
| Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. | The Journal of biological chemistry 20061020 |
| Epigenetic cancer therapy makes headway. | Journal of the National Cancer Institute 20061018 |
| Synthesis of rigid trichostatin A analogs as HDAC inhibitors. | Bioorganic & medicinal chemistry letters 20061015 |
| Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. | Journal of medicinal chemistry 20061005 |
| PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. | Annals of hematology 20061001 |
| Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. | Nature chemical biology 20061001 |
| Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061001 |
| Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA. | Bioorganic & medicinal chemistry letters 20060915 |
| Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. | Cancer research 20060915 |
| Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060915 |
| Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. | Journal of neuro-oncology 20060901 |
| Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060901 |
| A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060818 |
| The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. | International journal of cancer 20060815 |
| Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. | Blood 20060815 |
| The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. | Human genetics 20060801 |
| Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. | Molecular cancer therapeutics 20060801 |
| SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. | International journal of cancer 20060701 |
| Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. | Experimental hematology 20060601 |
| Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. | Bioorganic & medicinal chemistry 20060515 |
| Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. | Cancer research 20060515 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Histone hyperacetylation is associated with amelioration of experimental colitis in mice. | Journal of immunology (Baltimore, Md. : 1950) 20060415 |
| Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. | The Journal of biological chemistry 20060414 |
| Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. | Oncogene 20060406 |
| M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. | Gynecologic oncology 20060401 |
| Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. | Cancer research 20060401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060401 |
| Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer. | Journal of the National Cancer Institute 20060315 |
| Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. | The Journal of biological chemistry 20060303 |
| Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. | International journal of oncology 20060301 |
| Human endometrial cytodifferentiation by histone deacetylase inhibitors. | Human cell 20060201 |
| Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. | Journal of medicinal chemistry 20060126 |
| 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. | Leukemia research 20060101 |
| SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. | Oncology reports 20060101 |
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101 |
| Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. | European journal of haematology 20060101 |
| Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. | Clinical lung cancer 20060101 |
| Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. | BMC cancer 20060101 |
| Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. | BMC cancer 20060101 |
| Histone deacetylase inhibitors in cancer therapy. | Cancer investigation 20060101 |
| Molecule of the month. Vorinostat. | Drug news & perspectives 20060101 |
| Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. | Anticancer research 20060101 |
| Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. | Endocrinology 20051201 |
| Crystal structure of a bacterial class 2 histone deacetylase homologue. | Journal of molecular biology 20051118 |
| Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. | Bioorganic & medicinal chemistry letters 20051101 |
| Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus. | Cancer research 20051101 |
| Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. | The Journal of investigative dermatology 20051101 |
| Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. | Leukemia 20051001 |
| Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. | The Journal of biological chemistry 20050923 |
| Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. | Leukemia 20050901 |
| Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. | Cancer research 20050901 |
| Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050901 |
| Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. | Clinical prostate cancer 20050901 |
| It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. | Cancer research 20050801 |
| Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. | Molecular cancer therapeutics 20050801 |
| Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. | Apoptosis : an international journal on programmed cell death 20050801 |
| Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. | Surgery 20050801 |
| A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. | Journal of medicinal chemistry 20050728 |
| Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. | Bioorganic & medicinal chemistry 20050701 |
| Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines. | Anti-cancer drugs 20050701 |
| Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. | Molecular and cellular biology 20050701 |
| Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. | Neoplasia (New York, N.Y.) 20050701 |
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050610 |
| The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. | Journal of cancer research and clinical oncology 20050601 |
| Novel histone deacetylase inhibitors in the treatment of thyroid cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050515 |
| Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. | Journal of medicinal chemistry 20050505 |
| The role of histone acetylation in SMN gene expression. | Human molecular genetics 20050501 |
| Modulation of radiation response by histone deacetylase inhibition. | International journal of radiation oncology, biology, physics 20050501 |
| Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. | Journal of neurochemistry 20050501 |
| Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. | Molecular pharmacology 20050401 |
| Histone deacetylase inhibitors in programmed cell death and cancer therapy. | Cell cycle (Georgetown, Tex.) 20050401 |
| Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. | Cancer research 20050315 |
| [Histone deacetylase inhibitors as a new generation of anti-cancer agents]. | Postepy higieny i medycyny doswiadczalnej (Online) 20050311 |
| Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. | Bioorganic & medicinal chemistry letters 20050301 |
| Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. | Investigational new drugs 20050301 |
| 4-Hydroxybenzoyl derivative from the aqueous extract of the hydroid Campanularia sp. | Journal of natural products 20050301 |
| Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. | Nature clinical practice. Oncology 20050301 |
| Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. | Journal of medicinal chemistry 20050224 |
| Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. | Bioorganic & medicinal chemistry letters 20050117 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. | International journal of molecular medicine 20050101 |
| Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. | Experimental hematology 20050101 |
| High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. | Rapid communications in mass spectrometry : RCM 20050101 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. | Cancer research 20041201 |
| Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. | Molecular cancer research : MCR 20041201 |
| Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. | The Journal of thoracic and cardiovascular surgery 20041101 |
| Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. | Molecular pharmacology 20041001 |
| Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. | Biochemical pharmacology 20040915 |
| Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. | Journal of immunology (Baltimore, Md. : 1950) 20040915 |
| Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. | Apoptosis : an international journal on programmed cell death 20040901 |
| Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. | Surgery 20040801 |
| Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. | The Journal of biological chemistry 20040730 |
| Requirement of histone deacetylase activity for signaling by STAT1. | The Journal of biological chemistry 20040716 |
| Suberanilohydroxamic Acid. Aton Pharma. | IDrugs : the investigational drugs journal 20040701 |
| Thiol-based SAHA analogues as potent histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20040621 |
| On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. | Journal of medicinal chemistry 20040617 |
| Role of oxidative enzymatic treatments on enzymatic hydrolysis of softwood. | Biotechnology and bioengineering 20040605 |
| Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. | Radiation research 20040601 |
| Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040601 |
| Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. | Journal of cellular biochemistry 20040515 |
| The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). | Cell cycle (Georgetown, Tex.) 20040501 |
| [Therapeutic targets in polyglutamine diseases]. | Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 20040501 |
| Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. | International journal of oncology 20040401 |
| 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. | Journal of medicinal chemistry 20040311 |
| Silent advances. | Environmental health perspectives 20040301 |
| 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity. | Journal of medicinal chemistry 20040226 |
| QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. | Bioorganic & medicinal chemistry letters 20040209 |
| Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040201 |
| Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. | Bioorganic & medicinal chemistry letters 20040119 |
| (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20040105 |
| Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates. | Bioorganic & medicinal chemistry letters 20031215 |
| Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. | Cancer research 20031201 |
| Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. | Molecular cancer therapeutics 20031201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20031201 |
| The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. | Blood 20031115 |
| Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. | Cancer research 20031101 |
| N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). | Journal of medicinal chemistry 20031009 |
| Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030901 |
| Phosphorus-based SAHA analogues as histone deacetylase inhibitors. | Organic letters 20030821 |
| Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. | Cancer research 20030801 |
| Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. | Bioorganic & medicinal chemistry letters 20030602 |
| Molecular sequelae of histone deacetylase inhibition in human malignant B cells. | Blood 20030515 |
| Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. | International journal of cancer 20030501 |
| Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. | Cancer research 20030501 |
| Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. | Blood 20030415 |
| Anticancer drug shows promise against lupus. | Drug discovery today 20030415 |
| Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). | The Journal of biological chemistry 20030404 |
| Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. | Blood 20030301 |
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. | Proceedings of the National Academy of Sciences of the United States of America 20030218 |
| Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. | The Journal of clinical investigation 20030215 |
| Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. | Anticancer research 20030101 |
| Trifluoromethyl ketones as inhibitors of histone deacetylase. | Bioorganic & medicinal chemistry letters 20021202 |
| One-step SFE-plus-C(18) selective extraction of low-polarity compounds, with lipid removal, from smoked fish and bovine milk. | Analytical and bioanalytical chemistry 20021101 |
| Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. | Journal of medicinal chemistry 20020718 |
| The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. | Experimental cell research 20020701 |
| Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). | Leukemia 20020701 |
| Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. | International journal of cancer 20020510 |
| Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. | Journal of medicinal chemistry 20020425 |
| Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. | Journal of medicinal chemistry 20020214 |
| Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. | Oncogene 20020117 |
| Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. | Anticancer research 20020101 |
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. | Cancer research 20011201 |
| Targeting aberrant transcriptional repression in leukemia: a therapeutic reality? | The Journal of clinical investigation 20011101 |
| Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. | The Journal of clinical investigation 20011101 |
| Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). | British journal of haematology 20011101 |
| The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. | Proceedings of the National Academy of Sciences of the United States of America 20010911 |
| 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. | Journal of medicinal chemistry 20010621 |
| Inhibitors of histone deacetylase are potentially effective anticancer agents. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010401 |
| Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. | Breast cancer research : BCR 20010101 |
| Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. | Blood cells, molecules & diseases 20010101 |
| Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. | Oncogene 20001123 |
| Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. | Oncogene 19991125 |